Company intelligence / Profile preview
REDNVIA
Songdo, Incheon, South Korearednvia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
REDNVIA’s lead asset RNV-1001 (repurposed Evogliptin) for CAVD has advanced to a large Phase II/III trial enrolling 867 patients across the US and Canada. The drug bypassed Phase I due to an established safety profile from its use as an antidiabetic agent. Commercial manufacturing capacity has been secured in Korea. No topline efficacy results have been published yet.
- Therapeutic areas
- EndocrinologyCardiovascular
- Modalities
- Small molecules (notably DPP-4 inhibitors such as Evogliptin)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
MOUs with global contract sales organizations including IQVIAmanufacturing partnership with ST Pharm and Dong-A ST for API and final product production
Beyond the preview
Go deeper on REDNVIA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REDNVIA.